GlassScriptPhysician profile
Fida Sawalha
NPI 1750545422
$4,061.69
in general payments reported to CMS, 2019-2025
41 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.50 · 2020: $243 · 2021: $20.88 · 2022: $379 · 2023: $472 · 2024: $699 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,321.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $589.66 | 2019-2025 | Evenity, Tepezza, Repatha |
| Insulet Corporation | $438.04 | 2020-2025 | Omnipod |
| Lilly USA, LLC | $322.00 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $257.80 | 2019-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $194.54 | 2024-2025 | Tymlos |
| Medtronic, INC. | $193.48 | 2022-2025 | Minimed 780g |
| Novo Nordisk INC | $178.37 | 2019-2025 | Ozempic, Rybelsus |
| Intra-Sana Laboratories | $166.84 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Abbvie INC. | $149.04 | 2019-2025 | Vraylar |
| Cequr Corporation | $134.26 | 2024-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $131.22 | 2024-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $106.35 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.13 | 2023-2025 | Jardiance |
| Mannkind Corporation | $98.62 | 2024-2025 | |
| Corcept Therapeutics | $81.80 | 2025 | Korlym |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $65.88 | 2024-2025 | Isturisa, Signifor Lar |
| Biowound Solutions, INC. | $65.33 | 2024 | Bio-Connekt |
| Beta Bionics, INC. | $56.36 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Verity Pharmaceuticals INC. | $49.43 | 2024-2025 | Tlando |
| Smith+Nephew, INC. | $49.27 | 2025 | Renasys Touch |
| Tolmar, INC. | $46.83 | 2024-2025 | Jatenzo |
| Averitas Pharma INC. | $45.49 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $44.40 | 2023-2025 | |
| Horizon Therapeutics Plc | $44.18 | 2023 | Tepezza |
| Currax Pharmaceuticals LLC | $42.74 | 2023-2024 | Contrave |
| Sequel Med Tech, LLC | $42.25 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $40.76 | 2022-2025 | Gvoke Hypopen |
| Intuity Medical INC | $36.01 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Alexion Pharmaceuticals, INC. | $33.67 | 2024 | Strensiq |
| Astellas Pharma US INC | $33.18 | 2025 | Veozah |
| Aimmune Therapeutics, INC. | $32.01 | 2025 | Zenpep |
| Bayer Healthcare Pharmaceuticals INC. | $25.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.35 | 2020 | |
| Ascensia Diabetes Care US INC. | $23.26 | 2024 | |
| Alvogen INC | $21.88 | 2025 | Teriparatide |
| Glaxosmithkline, LLC. | $21.82 | 2020 | |
| Abbott Laboratories | $19.86 | 2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $18.92 | 2024 | Xyosted |
| Boston Scientific Corporation | $15.80 | 2023 | Superion Indirect Decompression System |
| Merck Sharp & Dohme LLC | $11.85 | 2020 | |
| Arbor Pharmaceuticals, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fida Sawalha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.